Zongertinib (Hernexeos®; Boehringer Ingelheim Pharmaceuticals, Inc.)received FDA accelerated approval on August 8th, 2025, for the treatment of adults with unresectable or metastatic non-squamous NSCLC harboring HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, following prior systemic therapy (FDA, 2025[35]). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.